CORNES-&-COMPANY-LTD.
Cornes & Company Ltd. started construction on THE MAGARIGAWA CLUB this past spring in Minamiboso in Chiba Prefecture. In creating the club, Cornes envisions a truly unique driving club, road course, and destination that will offer experiences unattainable at other racing circuits . Located 60minutes from the Tokyo metro area, Tokyo International Airport, and Narita International Airport, the exclusive driving club allows members to enjoy an unparalleled driving experience and spectacular views of Mt. Fuji and Tokyo Bay. In addition to its distinctive 3.5-kilometer driving course, THE MAGARIGAWA CLUB offers recreational options for everyone—not just car enthusiasts.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200813005038/en/
The first round of applications for membership are sold out.
Concept
There are a few legendary racetracks in the world today. These spots gain iconic status, becoming destinations for piston-heads. Aiming to put THE MAGARIGAWA CLUB on the map, too, Cornes wants to turn it into an iconic destination by creating an exceptional, world-class driving club.
The name and logomark of the club are based on the kanji “<<<(magarigawa)”. Cornes hopes that MAGARIGAWA’s members will be able to fully immerse themselves in the beautiful natural landscape allowing them to become one with nature and have experiences that they won’t get anywhere else in the world.
Road course
The driving course was designed by the world renown team at Tilke Engineers & Architects. It is the first course in Japan that the team has designed from scratch and features a maximum ascent of 20%, maximum descent of 16%, and an 800-meter long straight, making it a track like no other. It is challenging but also designed for safety, letting drivers focus on the driving experience. Members can drive their automobiles on the course, store them on site, and get maintenance checks before and after driving. They can take one-on-one lessons with professional instructors and explore the potential of their favorite cars in a safe manner. The climate-controlled pit building can accommodate up to 36 vehicles and there are other services and facilities that help ensure a satisfying driving experience.
Other Major Facilities
Clubhouse
The design of the clubhouse combines elements from both traditional Japanese and contemporary architecture. Inside the clubhouse members will find a bar, restaurant, family lounge, gymnasium, 25m swimming pool, spa facilities, and natural hot spring baths. Outside, there is a playground, dog run, and hiking trails.
Owner’s paddocks and long-term garage
Each owner’s paddock provides private indoor parking for up to 4 automobiles and features a spacious floorplan that includes a dining area, living room, and terrace. There is also a long-term car storage facility which is highly secure and climate controlled. On-site mechanics keep members’ vehicles in top condition for driving.
“Magarigawa will be home for car lovers. A sanctuary where members will be able to enjoy and share their passion with friends and family.”
said Kenzo Watari, CEO, Cornes Group.
“It will be the answer to the perennial question – where do you drive an 800 horsepower supercar?”
“The extremely hilly topography offers an astonishing basis for the track and makes the layout absolutely unique in the world.”
said Dr. Carsten Tilke, Managing Director, Tilke Engineers & Architects. “Although we have designed and realized over 80 racetracks worldwide including 19 Formula One circuits, this project was very special to us and we are proud to be part of it.
Drivers will enjoy mid-speed, technical sections as well as two high-speed straights of the 3.5km track, which incorporates highest safety and environmental standards. It will be ideal for all kinds of driver skills. As a car enthusiast and racing driver myself, I can’t wait to drive my first laps at this amazing unique track.”
For more information, visit www.magarigawa.com .
Overview
Name: THE MAGARIGAWA CLUB
Location: Minamiboso, Chiba Prefecture, Japan
Date of opening: Scheduled for late 2022
Total site area: 1,000,000sq.m
Track specs: 3.5km in length, max. ascent: 20%, max. descent: 16%, 800m long straight, 22 corners, elevation change of 250m
Convenient: 60minutes from Tokyo & Haneda Airport
About Cornes & Company Ltd.
Established in 1861, Cornes & Co., Ltd. specializes in the import and sale of electronic components, systems equipment, industrial machinery, laboratory equipment and scientific instruments, apparels, fragrances, kitchenware, and nautical charts and publications and has expanded its business into a wide range of areas including non-life insurance and marine insurance survey. Its subsidiary companies Cornes Motors Ltd. and C.P.S. Ltd, are authorized distributors of Rolls-Royce, Bentley, Ferrari, Lamborghini, and Porsche automobiles. Cornes Motors is the leading ultra luxury automotive dealership in Japan.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200813005038/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
